Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.37 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.37 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.36 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | BRD2 | P25440 | 1/20 | 0.34 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2957566 | 0.88 | OPRK1 (0.39) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2263552 | 0.88 | OPRK1 (0.39) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2266795 | 0.87 | OPRK1 (0.39) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2264547 | 0.87 | OPRK1 (0.38) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2266008 | 0.84 | OPRK1 (0.42) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2266190 | 0.83 | OPRK1 (0.40) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2962352 | 0.82 | OPRK1 (0.40) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2267890 | 0.82 | TP53 (0.44) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2268118 | 0.81 | OPRK1 (0.39) | OPRK1NR1I2ADORA3HTR2CADRA1A | |
| SCHEMBL2263970 | 0.80 | OPRK1 (0.49) | OPRK1PDE4DLMNAPDE3AROCK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-15 | — | — | US | disclosed |
| US-8242109-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110195959-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2011-08-11 | — | — | US | disclosed |
| US-7851465-B2 | Compositions and methods relating to novel compounds and targets thereof | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2010-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110195959-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | OPRK1 313/4885NR1I2 1849/4885ADORA3 693/4885 |
| US-20120289498-A1 | Compositions And Methods Relating To Novel Compounds And Targets Thereof | BAX, BAD, BAK1 | OPRK1 313/4885NR1I2 1849/4885ADORA3 693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.